Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Operating Margin: 2020-2025

Historic Operating Margin for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -2.78%.

  • GeneDx Holdings' Operating Margin rose 734.00% to -2.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.48%, marking a year-over-year increase of 2406.00%. This contributed to the annual value of -7.60% for FY2024, which is 8155.00% up from last year.
  • Per GeneDx Holdings' latest filing, its Operating Margin stood at -2.78% for Q3 2025, which was down 131.92% from 8.73% recorded in Q2 2025.
  • GeneDx Holdings' 5-year Operating Margin high stood at 9.21% for Q4 2024, and its period low was -529.56% during Q4 2022.
  • For the 3-year period, GeneDx Holdings' Operating Margin averaged around -37.12%, with its median value being -15.00% (2024).
  • Its Operating Margin has fluctuated over the past 5 years, first slumped by 35,302bps in 2022, then soared by 48,489bps in 2023.
  • Over the past 5 years, GeneDx Holdings' Operating Margin (Quarterly) stood at -200.31% in 2021, then crashed by 32,925bps to -529.56% in 2022, then spiked by 48,489bps to -44.66% in 2023, then surged by 5,387bps to 9.21% in 2024, then skyrocketed by 734bps to -2.78% in 2025.
  • Its Operating Margin stands at -2.78% for Q3 2025, versus 8.73% for Q2 2025 and -5.22% for Q1 2025.